Correction to “Characterization of Ubrogepant: A Potent and Selective Antagonist of the Human Calcitonin Gene–Related Peptide Receptor”

In the above article [Moore E, Fraley ME, Bell IM, Burgey CS, White RB, Li C-C, Regan CP, Danziger A, Stranieri M, Hostetler E, Banerjee P, and Salvatore C (2020) *J Pharmacol Exp Ther*, 373: 160-166; DOI: https://doi.org/10.1124/jpet.119.261065], the principal investigators who conducted the human capsaicin-induced dermal vasodilation study were inadvertently omitted from the Acknowledgments. The corrected version of the Acknowledgments is provided below.

The authors would like to acknowledge Jan N. de Hoon, Marleen Depré (both from Center for Clinical Pharmacology, University Hospitals Leuven and the Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Belgium), Tom Reynders (MSD Europe, Inc., Brussels, Belgium), and Eugene Marcantonio (Merck & Co., Inc. Kenilworth, NJ) for the human capsaicin-induced dermal vasodilation assay model design and conduct, and John Paleza (Merck & Co., Inc., Kenilworth, NJ) for the human capsaicin-induced dermal vasodilation assay data analysis. Writing and editorial assistance were provided to the authors by Peloton Advantage, LLC, Parsippany, NJ, and was funded by Allergan plc. The opinions expressed in this article are those of the authors. The authors received no honorarium/fee or other form of financial support related to the development of this article. The authors would like to acknowledge Mona Purcell for conducting the monkey PET studies, Mangay Williams for analytical support, Aniket Joshi for PET data analysis, and Abhijeet Jakate for assistance writing the manuscript.

The authors apologize for any inconvenience caused by this error.

The HTML and PDF versions of the article have been corrected.